For active psoriatic arthritis (PsA) in adult TNFi‑IR patients1

Exceptional access is already here. RINVOQ has achieved 99% preferred commercial coverage
Defy Expectations

Challenge treatment goals in PSA

*RINVOQ is on a preferred tier or otherwise has preferred status on the plan's formulary.
†Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

IR=intolerance or inadequate response; TNFi=tumor necrosis factor inhibitor

Efficacy Results with RINVOQ

Hear from Dr. Evan Siegel, MD, FACP, FACR and Dr. Rachel Tate, DO, FACR about skin and joint efficacy data, safety data, and RINVOQ as an option for adult patients with active PsA who have not achieved their treatment goals on a TNF inhibitor.

Well-Studied Safety Profile

Watch Dr. Evan Siegel, MD, FACP, FACR and Dr. Rachel Tate, DO, FACR discuss the long-term safety profile of RINVOQ across indications—an important consideration prior to prescribing RINVOQ for patients who continue to have symptoms despite previous treatment with a TNF inhibitor.


MEET THE FEATURED PHYSICIANS


RINVOQ met its primary objective ACR20 response
in two clinical studies1

Significant ACR20 Response at Week 12 (primary endpoint) vs placebo3,4

Significant ACR20 Response at Week 12 (primary endpoint) vs placebo3,4

SELECT-PsA 2 ACR20 response at Week 12
SELECT-PsA 1 ACR20 response at Week 12

Rapid ACR20 response seen as early as WEEK 2 3

Rapid ACR20 response seen as early as WEEK 2 3

SELECT-PsA 2: 33% RINVOQ 15 mg vs 11% placebo (NRI)3

SELECT-PsA 2: 33% RINVOQ 15 mg vs 11% placebo (NRI)3

SELECT-PsA 2 Study Design Intro:1
24‑week, double‑blind, placebo‑controlled study of 642 adult patients with moderately to severely active PsA who had an inadequate response or intolerance to at least one biologic DMARD. Patients were randomized to receive upadacitinib or placebo. The primary endpoint was proportion of patients achieving ACR20 response at Week 12 vs placebo.

SELECT-PsA 1 Study Design Intro:1
24-week, double‑blind, placebo and active comparator-controlled study of 1705 adult patients with moderately to severely active PsA who had an inadequate response or intolerance to at least one non‑biologic DMARD. Patients were randomized to receive either upadacitinib, active comparator, or placebo. The primary endpoint was proportion of patients achieving ACR20 response at Week 12 vs placebo.

Data Limitations: Week 2 data for all comparisons were not adjusted for multiplicity; therefore, statistical significance has not been established.

ACR=American College of Rheumatology; ACR20=improvement of at least 20% in tender joint count, swollen joint count, and at least 3 other core criteria; DMARD=disease‑modifying antirheumatic drug; IR=intolerance or inadequate response; NRI=nonresponder imputation; QD=once per day; TNFi=tumor necrosis factor inhibitor

RINVOQ is a once-daily JAK inhibitor1

Powerful
Disease Control3,5,6

  • Minimal Disease Activity (MDA) at Week 24
  • Data observed up to ~3 years

Durable
Joint Efficacy1,3-6

  • ACR20/50/70 responses at Week 12
  • Complete resolution of enthesitis (LEI=0) and dactylitis (LDI=0) evaluated at Week 24
  • Data observed up to ~3 years
  • ΔmTSS* evaluated at Week 24, with data up to ~1 year

*∆mTSS was evaluated in non-bDMARD-IR patients. RINVOQ is indicated for TNFi-IR patients.6

Effective
Skin Clearance1,3,5,6

  • PASI 75 at Week 16
  • Data in PASI 75 and additional skin measures observed up to ~3 years

RINVOQ is not indicated for the treatment of plaque psoriasis

Safety Data from 21 Clinical Trials Across 6 Indications1,7,†

  • >11,300 patients in global clinical trials across US-approved indications, including pediatrics 12+ years in AD7,
  • >31,200 patient-years of exposure to RINVOQ 15, 30, or 45 mg7,
  • >6.5 years max. exposure in RA (~4 yrs median) to RINVOQ 15 mg as of 8/15/227,

Exceptional Access and Patient Support

  • >95% preferred national commercial and Medicare Part D formulary coverage under the pharmacy benefit as of April 20232,§,||
  • 1:1 support to help PsA patients start and stay on track with their prescribed treatment plan

†Includes 2 phase 3 PsA trials, 3 phase 2 trials and 6 phase 3 RA trials, 1 phase 2/3 and 1 phase 3 AS trials, 1 phase 3 nr-axSpA trial, 1 phase 2 and 3 phase 3 AD trials, and 3 phase 3 UC trials. PsA: RINVOQ 15 mg, upadacitinib 30 mg; RA: RINVOQ 15 mg, upadacitinib 30 mg; AS: RINVOQ 15 mg; nr-axSpA: RINVOQ 15 mg; AD: RINVOQ 15 mg and 30 mg; UC: RINVOQ 15 mg, 30 mg, and 45 mg. RINVOQ 15 mg is the approved dose in PsA, RA, AS, and nr-axSpA; RINVOQ 15 mg and 30 mg are the approved doses in AD; RINVOQ 15 mg, 30 mg and 45 mg are the approved doses in UC.1,7

In PsA: ~5.0 years maximum exposure (~2.9 years median) to RINVOQ 15 mg as of 08/2022; In AS: ~3.8 years maximum exposure (~1.7 years median) to RINVOQ 15 mg as of 08/2022. In nr-axSpA: ~2.4 years maximum exposure (~1.0 years median) to RINVOQ 15 mg as of 08/2022.7

§RINVOQ is on a preferred tier or otherwise has preferred status on the plan's formulary.

||Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

ACR20/50/70=improvement of at least 20%/50%/70% in tender joint count, swollen joint count, and at least 3 other core criteria; AD=atopic dermatitis; AS=ankylosing spondylitis; DMARD=disease-modifying antirheumatic drug; IR=intolerance or inadequate response; LDI=Leeds dactylitis index; LEI=Leeds enthesitis index; max.=maximum; mTSS=modified total Sharp score; nr-axSpA=non-radiographic axial spondyloarthritis; PASI 75=at least 75% reduction in psoriasis area severity score from baseline; RA=rheumatoid arthritis; TNFi=tumor necrosis factor inhibitor; UC=ulcerative colitis

Join an upcoming educational speaker program webinar Join an upcoming educational speaker program webinar Join an upcoming educational speaker program webinar